LEO Pharma

LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones

16.11.2026 10:00:00 CET | LEO Pharma | Pressemeddelelse

Del

Ballerup, Denmark, 16 November, 2026 - In 9M 2026, LEO Pharma delivered strong innovation-led growth, with a significantly improved gross margin and continued investment in innovation. In September, LEO Pharma completed the acquisition of dersimelagon, an investigational first-in-class oral therapy now under FDA Priority Review, marking an important strategic milestone. Momentum continued after the period, with new approvals for Anzupgo® in Europe and China, further extending the product’s reach and underscoring LEO Pharma’s commitment to advancing innovation in dermatology.

Financial highlights

  • LEO Pharma’s revenue increased by 9% to DKK 10,961 million for 9M 2026, and by 11% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) with Rest of World (10% at CER) and Europe (1% at CER) also contributing.
  • Revenue from the Dermatology portfolio grew by 13% (CER), driven by the Innovative brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had a revenue increase of 49% (CER), while revenue from the Established brands was broadly unchanged (0% CER) compared to 9M 2025. Sales in the Critical Care portfolio grew by 2% (CER).
  • Adjusted EBITDA amounted to DKK 1,873 million in 9M 2026 (9M 2025: DKK 2,105 million) reflecting an adjusted EBITDA margin of 17% (9M 2025: 21%) amid significantly increased strategic investments in commercial and innovation activities, which more than offset expansion in the gross margin.
  • Net profit for 9M 2026 was DKK 679 million (9M 2025: DKK 2,036 million). Excluding non-recurring items and adjustments to the deferred tax asset, net profit improved by 10% to DKK 391 million in 9M 2026.
  • Free cash flow was an outflow of DKK 1,057 million for 9M 2026 (9M 2025: inflow of DKK 1,760 million) following the upfront payment for dersimelagon in September 2026 resulting in net interest-bearing debt of DKK 10,438 million at 30 September 2026 (YE 2025: DKK 9,358 million). Excluding BD&L, free cash flow improved by DKK 254 million to DKK 1,074 million in 9M 2026.

Innovation highlights

  • Acquisition of dersimelagon from Tanabe Pharma, successfully closed in September, adding a first-in-class oral MC1R agonist for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to LEO Pharma’s pipeline. Leveraging its commercial, medical affairs and market access capabilities, LEO Pharma is preparing for a potential U.S. launch in 2027, subject to FDA approval. Also in September the FDA granted Priority Review to the New Drug Application, with a PDUFA date expected by end of February 2027.
  • In October, Anzupgo® (delgocitinib) cream became the first therapy in the EU specifically approved for adolescents aged 12 to 17 with moderate-to-severe chronic hand eczema (CHE), following approval of the extended indication by the European Commission.
  • In November, China’s NMPA approved Anzupgo® (delgocitinib) cream for adults with moderate-to-severe CHE. Supported by positive results from the Phase 3 DELTA China trial, the approval further enables the global roll-out of Anzupgo®.

2026 outlook reaffirmed

  • For 2026, the outlook for revenue growth of 9-11% at CER, and adjusted EBITDA margin of 14-16%, is unchanged.

"We delivered a strong first nine months of 2026, reflecting the momentum we are building across our business. The global roll-out of Anzupgo® continues to expand and the uptake of Spevigo® is accelerating. In addition, we have acquired dersimelagon and are rapidly advancing preparations for its potential launch, in anticipation of an FDA decision expected in late February 2027. As the impact of our global platform continues to grow, we are better positioned to bring differentiated treatments to more patients and shape the future of medical dermatology,” said Christophe Bourdon, CEO of LEO Pharma.

Kontakter

Vedhæftede filer

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves more than 100 million patients in over 70 countries annually. LEO Pharma is ultimately co-owned by the LEO Foundation (majority shareholder) and Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of more than 4,400 people worldwide.

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China13.11.2026 08:00:00 CET | Pressemeddelelse

Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7 The approval reflects LEO Pharma’s commitment to improving care for adults living with moderate to severe chronic hand eczema in China, an exciting and important market for the company.

LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse

Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3

LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse

New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5

LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse

LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.

LEO Pharma receives positive CHMP opinion recommending Anzupgo® (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU18.9.2026 10:00:00 CEST | Pressemeddelelse

The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate. If approved by the European Commission, Anzupgo® would become the first therapy in the EU specifically approved for adolescents with moderate to severe chronic hand eczema, a patient population for whom there are currently no specifically approved treatment options. The positive CHMP opinion is supported by results from DELTA TEEN, a phase 3 trial investigating the efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema.1

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye